Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase

Richard M. Bergenstal, William V. Tamborlane, Andrew Ahmann, John B. Buse, George Dailey, Stephen N. Davis, Carol Joyce, Bruce A. Perkins, John B. Welsh, Steven M. Willi, Michael A. Wood

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


OBJECTIVE - To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS - The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS - A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P<0.001). A1C values remained reduced in the SAP group. After 3months on the SAP system, A1C decreased to 7.6%in the crossover group (P<0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS - Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.

Original languageEnglish (US)
Pages (from-to)2403-2405
Number of pages3
JournalDiabetes care
Issue number11
StatePublished - Nov 2011

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing


Dive into the research topics of 'Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase'. Together they form a unique fingerprint.

Cite this